Skip to main content
. 2011 Dec 21;23(1):155–164. doi: 10.1681/ASN.2010080858

Figure 4.

Figure 4.

Monoclonal anti-PR3 antibody induces sFlt1 release from monocytes. (A) An anti-PR3 mAb (10 μg/ml) induced sFlt1 release by human monocytes as early as 4 hours of incubation. sFlt1 release peaked at 8 hours and remained significantly increased at 16 hours. Further addition of C5a (10 nM) for 2 hours did not alter sFlt1 release. Data are from five independent experiments. CT, isotype-matched control. §P<0.001 versus 2-hour, 4-hour, and IgG isotype-matched control (CT) groups. #P<0.01 versus 2-hour, 4-hour, and IgG CT groups. (B) An anti-MPO mAb (10 μg/ml) induced a mild sFlt1 release by human monocytes only after 16 hours of incubation. Further addition of C5a (10 nM) for 2 hours did not alter sFlt1 release. Data are from three to four independent experiments. #P<0.01 versus 2-hour, 4-hour, and IgG CT groups. (C) Polyclonal anti-MPO antibody (10 μg/L) purified from 3 patients with anti-MPO vasculitis induced a very mild increase in sFlt1 release by human monocytes after 8 and 16 hours of incubation. Further addition of C5a (10 nM) for 2 hours did not alter sFlt1 release. Polyclonal anti-MPO IgG from each patient were tested in three independent experiments.